Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
Volume 49, Issue 20
Displaying 1-15 of 15 articles from this issue
ORIGINAL ARTICLES
  • Hiroaki Kusunoki, Ken Haruma, Jiro Hata, Manabu Ishii, Tomoari Kamada, ...
    2010 Volume 49 Issue 20 Pages 2195-2202
    Published: 2010
    Released on J-STAGE: October 15, 2010
    JOURNAL OPEN ACCESS
    Background Rikkunshito, a traditional Japanese (Kampo) medicine, is widely prescribed as an oral preparation for the treatment of functional dyspepsia (FD). In our previous study, we reported that extracorporeal ultrasonography (US) is a useful technique for the assessment of the gastric accommodation reflex (AR) and duodenogastric motility. In this study, we examined the effects of Rikkunshito on the gastroduodenal function in patients with FD.
    Methods Sixteen FD patients (median age, 45 y) underwent US, before and after 14 days of treatment with Rikkunshito (7.5 g b.d.). For assessment of the AR, a cross-sectional area of the proximal stomach was measured after incremental ingestion of a liquid meal up to 400-mL. The expansion rate was used as the parameter to determine the AR. Then, the gastric emptying rate (GER), motility index (MI), and reflux index (RI) were evaluated using previously reported methods.
    Results Although no significant changes were observed in the total score of the Gastrointestinal Symptom Rating Scale (GSRS), the scores of 3 of the 15 symptoms of GSRS decreased significantly after treatment with Rikkunshito. The expansion rate of the proximal stomach was significantly greater after treatment with Rikkunshito than before the treatment. Although the GER and MI increased significantly, no significant differences in the RI were observed after treatment with Rikkunshito.
    Conclusion These observations suggested that Rikkunshito may be beneficial for the treatment of FD patients with impaired AR and gastric motility. These results also suggested that Rikkunshito has a therapeutic potential for FD and GERD.
    Download PDF (280K)
  • Yingyu Wang, Zhaohui Wang, Weiming Wang, Hong Ren, Wen Zhang, Nan Chen
    2010 Volume 49 Issue 20 Pages 2203-2209
    Published: 2010
    Released on J-STAGE: October 15, 2010
    JOURNAL OPEN ACCESS
    Background Patients with congenital solitary kidney have an increased risk of developing hypertension, proteinuria and renal insufficiency. However, the specific factors associated with the progression of renal function in adults with congenital solitary kidney remain still unclear. The purpose of this study was to identify factors that are independently associated with renal function progression in patients with congenital solitary kidney.
    Methods Sixty-five Chinese adults with congenital solitary kidney (48 patients with unilateral renal agenesis and 17 with severe unilateral renal dysplasia) were recruited into our study retrospectively. Clinical data were analyzed.
    Results Of sixty-five patients with congenital solitary kidney, the prevalence of hypertension, proteinuria and renal insufficiency was 36.9%, 35.4% and 38.5%, respectively. There was no significant difference in the glomerular filtration rate (GFR) between patients with and without hypertension, whereas GFR in patients with proteinuria was significantly lower than in those without proteinuria (p<0.05). While there was no statistically significant difference in prevalence of hypertension between patients with and without renal insufficiency, the prevalence of proteinuria in patients with renal insufficiency was significantly higher than in those without renal insufficiency (p<0.05). Logistic regression analysis revealed that kidney length and proteinuria were independently associated with the progression of renal function (OR=0.20, 95%CI 0.05-0.79, and OR=8.30, 95%CI 2.30-29.96, respectively).
    Conclusion Hypertension, proteinuria or renal insufficiency was present in approximately one-third of adults with congenital solitary kidney. Those with a kidney length of less than 120 mm or proteinuria had a much higher risk of renal insufficiency.
    Download PDF (676K)
  • Kunihiro Ichinose, Tomoki Origuchi, Shin-ya Kawashiri, Naoki Iwamoto, ...
    2010 Volume 49 Issue 20 Pages 2211-2218
    Published: 2010
    Released on J-STAGE: October 15, 2010
    JOURNAL OPEN ACCESS
    Objective Mizoribine (MZR) is an immunosuppressant that inhibits nucleic acid metabolism and is a relatively safe disease-modifying anti-rheumatic drug (DMARD). We evaluated the efficacy and safety of one single dose per day for patients with rheumatoid arthritis (RA).
    Patients and Methods In this study 32 patients with RA received MZR therapy. We evaluated the average dose of MZR and prednisolone, response to treatment and peak plasma level of MZR.
    Results The average dose of MZR was 146.1±31.2 (range: 50-200) mg/day. The average dose of prednisolone was 4.63±3.59 (range: 0-14) mg/day. The average plasma level of MZR, measured after 3 hours, was 2.20±0.49 μg/mL in the responder group and 1.59±0.82 μg/mL in the non-responder group (p=0.020). The treatment with MZR for 24 weeks was completed by 71.9% of patients and the proportion of patients who achieved a good and moderate response rate according to the European League Against Rheumatism (EULAR) criteria was 56.3% at 24 weeks. The plasma level of MZR which was greater than or equal to 2.12 μg/mL was significantly correlated with the clinical response (p<0.01). Only one of thirty-two cases discontinued the treatment, because of skin eruption.
    Conclusion This study included patients that could not be treated with other DMARDs and/or biologic agents because of age, interstitial pneumonia and other complications. We show that MZR may be a useful and relatively safe therapy for patients in this group.
    Download PDF (2010K)
  • Yuh-Shan Ho, Hiroaki Satoh, Shih-Yuan Lin
    2010 Volume 49 Issue 20 Pages 2219-2228
    Published: 2010
    Released on J-STAGE: October 15, 2010
    JOURNAL OPEN ACCESS
    Objective This study was undertaken to explore a bibliometric approach to quantitatively assess current research trends in lung cancer in Japan, using the related literature in the Science Citation Index (SCI) database from 1991 to 2008.
    Materials and Methods Articles were analyzed by the scientific output and research performances of individuals, institutes, and collaborative countries with Japan. Distribution of words in the article title, author keywords, and KeyWords Plus in different periods was applied to evaluate research trends by the frequency of keywords used.
    Results Keyword analysis indicated that there has been a strategy to connect molecular biology with clinical practice. Researchers in Japan have published high impact articles related to non-small cell and small cell lung cancer.
    Conclusion Finally, this study highlights the topics in lung cancer research that are becoming popular in Japan.
    Download PDF (683K)
CASE REPORTS
PICTURES IN CLINICAL MEDICINES
feedback
Top